Isogenica specialises in the discovery of therapeutic and diagnostic peptides and proteins using its proprietary technology, CIS display. Established in 2000, and now based south of Cambridge UK at Chesterford Research Park, Isogenica has developed into a world leader in the field of peptide engineering.

Isogenica has developed a powerful platform technology, known as CIS display, that enables the discovery of novel peptide and protein therapeutics from vast pools, or libraries, of genes. CIS display enables the creation of libraries encoding upto 10¹⁴ different clones and the selection of superior polypeptides from these.

Isogenica works in partnership with pharmaceutical and biotechnology companies to rapidly select and engineer high quality peptide candidates using CIS display. CIS display is also available to license for scaffolds and larger proteins, such as single chain antibodies (please click for details).

Isogenica has partnered with over a dozen leading pharma and biotech companies in the discovery of novel peptides for therapeutic and non-therapeutic applications or for licenses. These include Amgen, Astra Zeneca, Centocor, GE Healthcare, Invitrogen, Johnson and Johnson, Pfizer, Smiths Detection Systems, UCB, Wyeth.